Lapatinib in the treatment of advanced breast cancer


Authors: J. Abrahámová 1;  L. Dušek 2;  P. Brabec 2;  R. Vyzula 3;  Z. Donátová 1
Authors‘ workplace: Onkologické oddělení Fakultní Thomayerovy nemocnice KOC FNB a 1. LF UK, Praha Vedoucí: prof. MUDr. Jitka Abrahámová, DrSc. 1;  Institut biostatistiky a analýz, Masarykova univerzita, Brno Ředitel: doc. RNDr. Ladislav Dušek, PhD. 2;  Masarykův onkologický ústav, Brno Ředitel: prof. MUDr. Jiří Vorlíček, CSc. 3
Published in: Prakt. Lék. 2011; 91(7): 417-421
Category: In diferent

Overview

The authors present data from the Czech drug registry concerning the use of lapatinib in combination with capecitabine in advanced breast cancer patients, whose tumours highly express ErbB2 (HER2). Despite patients’ substantial previous treatment we can demonstrate the efficacy of lapatinib; the Czech data is comparable to the results of the registration study.

Key words:
lapatinib, ErbB2(HER2), advanced breast cancer, Czech drug registry.


Sources

1. Cameron, D., Casey, M., Oliva, C. et al. Lapatinib plus Capecitabine in women with HER-2-positive advanced breast cancer: Final survival analysis of a phase III randomized trial. Oncologist 2010, 15, p. 924-934.

2. Cameron, D., Casey, M., Press, M. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Update efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008, 112, p. 533-543.

3. Di Leo, A., Gomez, H.L., Aziz, Z. et al. Phase III, double-blind randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 2008, 26, p. 5544-5552.

4. Geyer, C.E., Forster, J., Lindquist, D. et al. Lapatinib plus capecitabine for HER2 - positive advanced breast cancer. N. Engl. J. Med. 2006, 355, p. 2733-2743.

5. Johnston, S., Pippen, J. Jr., Pivot, X. et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor – positive metastatic breast cancer. J. Clin. Oncol. 2009, 27, p. 5538-5546.

6. Nahta, R., Esteva, FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8, p. 215-222.

7. Rusňák, D.W., Lackey, K., Affleck, K. et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, p. 85-94.

8. Schwartzberg, L.S., Franco, S.X., Florance, A. et al. Lapatinib plus letrozole as first –line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15, p. 122-129.

9. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl. J. Med. 2001, 344, p. 783-792.

Labels
General practitioner for children and adolescents General practitioner for adults
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account